Autologous stem cell transplantation for relapsed/refractory diffuse large B-cell lymphoma: efficacy in the rituximab era and comparison to first allogeneic transplants. A report from the EBMT Lymphoma Working Party

. 2016 Mar ; 51 (3) : 365-71. [epub] 20151130

Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic

Typ dokumentu klinické zkoušky, srovnávací studie, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid26618550

In the era of chemoimmunotherapy, the optimal treatment paradigm for relapsed and refractory diffuse large B-cell lymphoma has been challenged. We reviewed the outcome of standard salvage therapy with an autologous stem cell transplant (autoSCT) over the last two decades and the outcome of allogeneic SCT (alloSCT) in the most recent decade. AutoSCT recipients diagnosed between 1992 and 2002 (n=2737) were compared with those diagnosed between 2002 and 2010 (n=3980). Patients diagnosed after 2002 had a significantly lower non-relapse mortality (NRM) and relapse incidence (RI) and a superior PFS and overall survival (OS). A total of 4210 patients diagnosed between 2002 and 2010 underwent either an autoSCT or an alloSCT as their first transplant procedure. Two-hundred and thirty patients received an alloSCT (myeloablative (MACalloSCT) n=132, reduced intensity (RICalloSCT) n=98). The 4-year NRM rates were 7%, 20% and 27% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year RI was 45%, 40% and 38% for autoSCT, RICalloSCT and MACalloSCT, respectively (NS). The 4-year PFS were 48%, 52% and 35% for autoSCT, RICalloSCT and MACalloSCT, respectively. The 4-year OS was 60%, 52% and 38% for autoSCT, RIC alloSCT and MACalloSCT, respectively. After adjustment for confounding factors NRM was significantly worse for patients undergoing alloSCT whilst there was no difference in the RI.

Zobrazit více v PubMed

Biol Blood Marrow Transplant. 2010 Jan;16(1):78-85 PubMed

J Clin Oncol. 2009 Jan 20;27(3):426-32 PubMed

J Clin Oncol. 2011 Apr 1;29(10):1342-8 PubMed

Biol Blood Marrow Transplant. 2007 Apr;13(4):486-92 PubMed

J Clin Oncol. 2003 Oct 15;21(20):3744-53 PubMed

Lancet Oncol. 2014 Jun;15(7):757-66 PubMed

N Engl J Med. 1995 Dec 7;333(23):1540-5 PubMed

Blood. 2003 Jul 1;102(1):53-9 PubMed

Br J Haematol. 1999 Oct;107(1):154-61 PubMed

J Clin Oncol. 2005 Aug 1;23(22):5027-33 PubMed

J Clin Oncol. 2012 Dec 20;30(36):4462-9 PubMed

Biol Blood Marrow Transplant. 2012 May;18(5):788-93 PubMed

Blood. 2007 Dec 15;110(13):4606-13 PubMed

Clin Lymphoma. 2000 Jun;1(1):46-54 PubMed

Biol Blood Marrow Transplant. 2014 Nov;20(11):1729-36 PubMed

Blood. 2003 Sep 15;102(6):1989-96 PubMed

Br J Haematol. 2005 Oct;131(2):223-30 PubMed

J Clin Oncol. 2001 Jan 15;19(2):406-13 PubMed

Br J Haematol. 2008 Nov;143(3):395-403 PubMed

Blood. 2002 Dec 15;100(13):4310-6 PubMed

Comput Methods Programs Biomed. 2004 Jul;75(1):45-9 PubMed

Biol Blood Marrow Transplant. 2010 Jan;16(1):35-45 PubMed

Blood. 1994 Aug 15;84(4):1050-5 PubMed

Bone Marrow Transplant. 2003 Apr;31(8):667-78 PubMed

N Engl J Med. 2002 Jan 24;346(4):235-42 PubMed

Bone Marrow Transplant. 2000 Oct;26(8):859-64 PubMed

Lancet Oncol. 2006 May;7(5):379-91 PubMed

J Clin Oncol. 2014 Nov 1;32(31):3490-6 PubMed

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace